Skip to content

Main Navigation

Vor Bio
  • About
  • Science
    • How It Works
    • Our Pipeline
    • Publications
  • Patients
    • Our Commitment To Patients
    • Generalized Myasthenia Gravis
    • Sjögren’s Disease (SD)
  • Careers
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Stock Quote & Chart
    • Contact IR
    • Email Alerts
    • Tax Information
  • Contact

Publication Type: Journal Publication

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

[…]

Read More… from A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis

[…]

Read More… from A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis

Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases

[…]

Read More… from Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

[…]

Read More… from Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial

[…]

Read More… from Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

[…]

Read More… from Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects

[…]

Read More… from Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects

Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis

[…]

Read More… from Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis

Share This Post

Logo Vor Biopharma White
  • About
  • Science
    • How It Works
    • Our Pipeline
    • Publications
  • Patients
    • Our Commitment To Patients
    • Myasthenia Gravis
    • Sjögren’s Disease (SD)
  • Careers
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Stock Quote & Chart
    • Contact IR
    • Email Alerts
    • Tax Information
  • Contact

© 2026 Vor Bio | Telitacicept is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.